Parmax Pharma Ltd

Parmax Pharma Ltd (PARMAX) is a micro-cap Healthcare company valued at ₹51 crore operating in Pharmaceuticals & Biotechnology on the NSE and BSE.

Recent price move

Parmax Pharma Ltd last traded at ₹136.4, modestly down 0.98% on the day.

Recent developments

2026-06-30: The company reported a net profit of ₹2 crore for the latest quarter, reversing a net loss of ₹1 crore in the same quarter a year earlier. 2026-06-30: The company also reported a net loss of ₹4 crore for the latest fiscal year, widening from a loss of ₹2 crore in the prior year.

Financial performance

The company's business is deteriorating, with annual revenue falling 57.1% and net profit turning into a loss that widened from ₹2 crore to ₹4 crore. The latest quarter saw revenue surge 323.7% to ₹8 crore, and net profit swung from a loss of ₹1 crore to a profit of ₹2 crore, indicating a recent turnaround in the quarter.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at -7.09 times book value.

Things to watch

The company is currently in a net loss, with a net profit margin of -34.3%, down 26.9 percentage points from the prior year. Revenue has declined for five consecutive years, with a 14.3% annual decline over the past five years. The return on capital employed is -85.8%, indicating poor efficiency in using capital.

Where it stands

Parmax Pharma Ltd ended the latest quarter with a net profit of ₹2 crore, reversing a loss from the same quarter a year earlier, but the company remains in a net loss for the latest fiscal year. The most significant movement was the sharp rise in revenue and net profit in the latest quarter, though the annual figures remain concerning.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.